Crescent Biopharma Share Price Today

Crescent Biopharma Q3 loss widens to $(0.90), revenue beats estimates

Crescent Biopharma Inc reported a Q3 loss of $(0.90) per share, missing the $(0.72) consensus estimate by 25%. Quarterly sales reached $3.117 million, beating the $312.500 thousand estimate by 897.44%. Loss per share increased 29.13% year-over-year from $(1.27) in the prior year period.

HC Wainwright reiterates Buy on Crescent Biopharma, holds $36 target

HC Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating on Crescent Biopharma. The $36 price target was maintained without change. The reiteration indicates sustained analyst confidence in the stock.

Crescent Biopharma expands CR-001 trial with chemo combos

Crescent Biopharma has completed dose escalation in the global Phase 1/2 ASCEND trial of CR-001, with over 125 patients dosed across the US, Europe, and South Korea. Enrollment has begun in standard of care chemotherapy combination cohorts for various solid tumors, including first-line NSCLC, colorectal, and gastric cancers. Initial monotherapy data from the ASCEND trial are expected in Q1 2027, while combination cohort data are projected for mid-2027. The company plans to initiate the first of multiple Phase 3 trials for CR-001 in early 2028, pending regulatory interactions and clinical results. Crescent anticipates more than 2,000 patients will be dosed across its entire portfolio by mid-2027, driven by partnerships with Kelun-Biotech.

Crescent Biopharma grants 81,525 inducement options to new hires

Granted options for 81,525 ordinary shares to six non-executive employees. Exercise price set at $13.94, matching the October 5, 2026 closing price. Awards approved under the 2025 Employment Inducement Incentive Award Plan. Vesting schedule includes a one-year cliff followed by monthly accruals.

Crescent Biopharma secures FDA IND clearance for CR-002 ADC

FDA cleared IND application for CR-002, a PD-L1 targeting ADC. Clinical trials for advanced solid tumors to begin Q4 2026. Initial data from Phase 1/2 APOLLO trial expected H2 2027. CR-002 is third program from Crescent to enter clinical stage.

Crescent Biopharma grants 31,200 inducement options at $14.24

Granted 31,200 stock options to two non-executive employees. Exercise price set at $14.24 per share, equal to closing price on Sept 24, 2026. Options have a 10-year term with a four-year vesting schedule. Grants made under the 2025 Employment Inducement Incentive Award Plan.